AAIC 2025: Comparison of Plasma pTau217 Assays on Different Platforms

Plasma pTau217 was recently discovered as a prominent blood-based biomarker in the early diagnosis of Alzheimer's disease (AD) in which it can discriminatively predict AD development decades ahead of symptom onset. Numerous pTau217 assays have been developed on different platforms with different detector antibodies, buffers, and calibrators, displaying difference detection performances (1-4). To compare the platform performing features, we selected 8 of them and did the head-to-head comparison of the pTau217 assays that have been comprehensively or newly explored in the immunoassays in clinical trials and/or LDT diagnostic applications.

"*" indicates required fields

First Name*

Last Name*

Company*

State*